Qinlock
Qinlock ingredients
| Active ingredient | Strength |
|---|---|
| Ripretinib | 50 mg/1 |
What Qinlock is used for
The FDA lists the approved uses on the official label (below). In the EU, ripretinib is approved as Qinlock for:
Qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Qinlock
- Generic name
- Ripretinib
- Made by
- Deciphera Pharmaceuticals, LLC
- Forms
- Tablet
- Given
- Oral
- Drug class
- Kinase Inhibitor
- FDA approval
- New drug application (NDA) NDA213973
- On the US market since
- 2020
Official information
- Qinlock prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Ripretinib)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Qinlock?
Qinlock (Ripretinib) is a cancer medicine made by Deciphera Pharmaceuticals, LLC, approved by the US FDA.
What are the ingredients of Qinlock?
Qinlock contains Ripretinib (50 mg/1).
Is Qinlock approved in Europe?
The same active substance is approved in the EU as Qinlock.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA